Introduction
Chronic graft-versus-host disease (cGVHD) is the most common late complication of allogeneic hematopoietic stem cell transplantation (HCT). It occurs in 60-80% of long-term survivors and causes significant morbidity and mortality. 1 GVHD that occurs in the first 100 days after HCT is considered acute and those patients that present with myriad clinical features often resembling autoimmune disorders, beginning approximately 100 days after allogeneic SCT (but manifestation may appear years later) are considered to have cGVHD. The incidence of cGVHD is likely to increase due to the greater use of unrelated donors, inclusion of older recipients, increasing use of donor leukocyte infusions, and perhaps with increasing use of peripheral blood stem cell transplantation (PBSCT). [2] [3] [4] [5] [6] With the increasing incidence of cGVHD, there might likewise be an increase in the clinical manifestations of cGVHD. Animal models of cGVHD describe the kidney as a target organ with histopathologic features of membranous glomerulonephritis (MGN). 7 However, renal involvement in humans with cGVHD is not well-established. Before this study, isolated case reports have documented nephrotic range proteinuria occurring after allogeneic transplantation, suggesting renal involvement may be a manifestation of cGVHD. Herein, we report a series of nine patients from a single institution that developed nephrotic syndrome (NS) after allogeneic hematopoietic stem cell transplantation, describing both the clinicopathologic features of the disease as well as response to treatment.
Patients and methods

Subjects and transplantation
Eight hundred and eighty-nine consecutive patients underwent allogeneic stem cell transplantation at the University of Michigan Medical Center between September 1994 and December 2002. Patients were transplanted on various clinical trials approved by the Institutional Review Board (IRB) or standard of care protocols. IRB consent was obtained for the retrospective review of these patients' charts and laboratory data to evaluate for the incidence of NS. Preparative regimens for transplantation were either myeloablative or reduced-intensity regimens. The choice of regimen depended on the status of the underlying malignancy and co-morbid factors of the patients. Patients older than 55 years of age and patients with significant co-morbid factors were treated with reduced-intensity regimens, otherwise myeloablative regimens were used. The source of hematopoietic stem cells was either marrow or peripheral blood. Marrow stem cell graft from the donor was harvested from the posterior iliac crest under general anesthesia. Peripheral blood stem cell graft was harvested after 5 days of G-CSF priming at the dose of 8 mcg/kg given subcutaneously twice a day.
All patients received GVHD prophylaxis consisting of tacrolimus and methotrexate. Tacrolimus 0.03 mg/kg was given by continuous intravenous (i.v.) infusion starting 48 h before stem cell infusion. The dose of tacrolimus was calculated according to patient's lean body weight. The route of administration was converted from i.v. to oral at the ratio of 1:4 when patients were able to tolerate oral intake. Dose adjustments were made as necessary to achieve a target level of 10-15 ng/ml during the first 8 weeks after transplantation. Provided that the patient was free from GVHD, starting on day 57 the tacrolimus dose was tapered by 20% every 4 weeks until it was discontinued on day 180. Methotrexate at 5 mg/M 2 was given on days 1, 3, 6 and 11 following transplantation. Patients who developed acute GVHD were treated initially with methylprednisolone 2 mg/kg/day and tacrolimus to maintain the blood level of 10-15 ng/ml. Additional immunosuppressants (e.g. mycophenolate, sirolimus and hydroxychloroquine) were given if patients did not respond to initial therapy. 1 Extracorporeal photopheresis was employed in selected patients in whom venous access was available. 8 Acute and cGVHD were assessed according to consensus and Seattle criteria, respectively.
9,10
Renal biopsy Renal biopsy specimens were fixed in formalin and glutaraldehyde for routine histopathology and electron microscopy, respectively. A portion was also snap frozen for immunofluoresence study. For light microscopy, the specimens were stained with hematoxylin-eosin, trichrome and silver stains. Special attention was paid to the deposition of the basement membrane and changes in the interstitial tubular areas. Direct immunofluorescence studies were carried out using FITC-conjugated antisera for IgG, IgA, IgM, C3, C4, C1q, albumin and fibrinogen on the snap frozen specimen. Ultrastructural examination was used to locate electron-densed deposits and to study the morphology of the foot processes of the epithelial cells.
Results
Patient characteristics
Among the transplanted patients, only those that presented with clinical symptoms of severe edema and had negative cardiac work-up and diarrhea were evaluated for NS. Nine patients were identified to have developed nephrotic range proteinuria. The median age of the patient at the time of transplant was 54 (range, 37-58).
Seven of these nine patients were recipients of matched sibling donor transplant (MSD); the remaining two patients received stem cell transplant from a matched unrelated donor (MUD). Both MUD patients received a reduced-intensity regimen previously described, while MSD recipients received myeloablative regimens specific for their underlying malignancy (Table 1 ). All patients, both MSD and MUD recipients, received G-CSF mobilized peripheral blood stem cell grafts matched at the allelic level for HLA-A, -B and -DR loci for MSD. Both recipients of MUD transplants, the DR and the A, B loci of recipient and donor were also matched at allele level. Four of the nine, including one of the two MUD recipients received sex-mismatched allo-graft. No common haplotype was noted in either of the haplotypes in the cases of MUD HCT. Urine analyses were performed on all patients before transplantation and none of the patients had evidence of nephrotic range proteinuria and none, including the myeloma patients, had evidence of pre-existing renal disease before transplant as determined by serum creatinine of o1.5 mg/dl. None of the patients were on amphotericin at the time of diagnosis. One of the nine eventually went to develop pulmonary aspergillosis after the diagnosis and treatment for cGVHD and NS. All of the patients, including those that were not on immuno-sppression were on penicillin prophylaxis as per our standard practice. None of the patients had evidence of streptococcal infection or sepsis at the time of diagnosis. The details of the cases are summarized in Table 1 .
Development of progressive edema and nephrotic range proteinuria was a late event occurring at a median of 735 days post-HCT (range 385-1278 days). The amount of proteinuria in 24 h urine collection ranged from 3.6 to 27 g. Seven out of nine patients at the time of diagnosis had evidence of hypercholesterolemia based on the NCEP guidelines (4240 mg/dl). A detailed analysis of the coagulation parameters including protein C levels was performed only in two patients and both were negative at the time of diagnosis. Serum albumin levels ranged from 1.1 to 2.4 g/dl. Seven patients had previously received treatment for symptomatic cGVHD before the development of proteinuria. Two patients developed nephrotic range proteinuria without other preceding clinical signs and symptoms of cGVHD. Of the seven patients who had a preceding history of cGVHD, four had completed and three were on a tapering schedule of immunosuppression at the onset of NS. Thus, the duration and dose of calcineurin inhibitor at the time of onset of NS was variable and ranged from none to sub-therapeutic levels of tacrolimus.
At the time of onset of albuminuria, two of the three multiple myelomas had bone marrow biopsy and the CLL and NHL patients had CT scans that were negative for relapse. All three of the myeloma patients showed no evidence of monoclonal Bence Jones proteins in the urine protein electrophoresis. All of the patients showed complete donor chimerism by peripheral blood VNTR analysis while none of them demonstrated other clinical or laboratory evidence of disease relapse.
Renal histopathology
Six of the nine patients underwent renal biopsy, two refused the procedure and one was treated empirically based on the clinical judgment of the treating HCT and Nephrology physicians. Five of the six patients had membranous glomerulonephritis on biopsy. This lesion, illustrated in Figure 1a , showed the characteristic appearance of a membranous process with diffuse thickening of the glomerular capillary loops and the absence of inflammatory response on light microscopy. On immunofluoresence, there was the characteristic granular capillary wall deposition pattern of IgG and C3. Ultrastructurally, there were numerous electron dense immune deposits present in subepithelial and intramembranous locations (arrows) (Figure 1b) . One patient receiving a reducedintensity transplant had minimal-change glomerular lesion. The glomeruli appeared normal on light microscopy (Figure 2a) , whereas by electron microscopy, there was widespread effacement of the foot processes of the epithelial cells (arrows) characteristic of this disease (Figure 2b ).
Response to therapy and clinical outcome
At the onset of NS, seven out of nine patients had cGVHD; four out of seven patients who had cGVHD were off all immunosuppression and the remaining three patients were still on immunosuppressive therapy. Two other patients had no clinical evidence of cGVHD at the onset of NS; one of these two patients was receiving an ACE inhibitor for hypertension at the onset of renal disease and his proteinuria resolved gradually over several months. Two patients were treated with Rituximab with excellent response. One of these two patients was off all immunosuppression and received rituximab as primary therapy for NS; the other patient responded to rituximab after failure of other immunosuppressive therapy. Seven patients received methylprednisolone in addition to ongoing immunosuppressants. These seven patients were hypertensive at the onset of renal disease or developed hypertension shortly after initiation of methylprednisolone, and required ACE inhibitors as treatment for elevated blood pressure. NS, as determined by improvement in proteinuria, improved in all of the nine patients (Table 1) . At the time of chart evaluation, seven of the nine patients were alive, one died from pulmonary aspergillosis and the other from sepsis.
Discussion
Nine of 889 patients undergoing allogeneic transplants from 1994 to 2002 developed NS, representing an overall incidence of 1% (95% confidence interval, 0.5%, 1.9%). Given that all of the transplant patients were not systematically and prospectively screened but only those patients that presented with clinical symptoms of NS were selected would clearly impact on the true incidence of NS. Of the 889 allogeneic transplants, 548 were transplanted from a matched sibling donor, for an incidence of 1.3% in such recipients. Among 383 sibling transplant patients who developed cGVHD, seven developed NS, an incidence of 1.8% (95% confidence interval, 0.7, 3.7%). Only one of 165 sibling allogeneic transplants without pre-existing cGHVD developed NS, an incidence of 0.6% (95% confidence interval, 0.0, 3.3%). We have thus observed NS correlating with the clinical course of cGVHD in a few patients, but a greater sample size would be needed to prove a significant association between the development of NS and cGVHD. Although a majority of the nine patients had B-cell malignancies (myeloma, NHL and CLL), there was no evidence of disease relapse or clonality in the proteinuria at the time of diagnosis. The myeloma patients, as the others had evidence of albuminuria, and no evidence of Bence Jones in their 24 h urine studies at the time of diagnosis. It might be possible that NS might occur more frequently in patients with B-cell neoplasms, but the clinical variables and the small numbers of cases preclude sufficient power for formal statistical analyses.
Fifteen cases of NS associated with cGVHD have been reported in the English literature. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In all these reports, similar to our series, the most common pathological finding on renal biopsy was membranous glomerulonephritis (11 of the 13) and much less commonly minimal change disease (two of 13). The diseases for which transplantation was performed included chronic myeloid leukemia, multiple myeloma, aplastic anemia and acute leukemia. With the exception of patients transplanted for aplastic anemia, the preparative regimens employed were all myeloablative and mostly included total body irradiation. While all stem cell grafts were from matched related donors, the source of stem cells included bone marrow for nine and peripheral blood for four patients. All of the reported cases in the literature received cyclosporine for GVHD prophylaxis, whereas our patients received tacrolimus. Twelve of the 13 had evidence of cGVHD at the time of diagnosis of NS. Renal disease as in our series was a late manifestation, ranging in onset seven to 24 months after transplantation. The NS in all of the reported cases responded to treatment with immunosuppression. With the temporal occurrence of NS in the setting of cGVHD in the majority of these patients, these observations suggest that the kidney is a target organ of cGVHD.
Renal damage after HSCT may be the result of the preparative regimen, the use of cyclosporine or tacrolimus given for GVHD prophylaxis, and/or other nephrotoxic agents received during or post-transplant. Renal involvement associated with cGVHD secondary to immunemediated glomerular damage is a rare event. Development of renal disease after allogeneic SCT occurring temporally with cGVHD would suggest that the kidney is also a target of this immune dysregulation. Neither underlying disease, age, race, sex, conditioning regimen, nor GVHD prophylaxis (cyclosporine or tacrolimus) seems to predict the development of NS after allogeneic HCT. The association of renal involvement by cGVHD with peripheral blood Nephrotic syndrome and chronic GVHD P Reddy et al stem cell transplantation in our series is intriguing since we had not previously observed NS in the setting of marrow transplantation at our institution. We have observed an increase in cGVHD since the greater use of PBSC instead of BM as the source of allografts. This is consistent with the recent observations of increasing reports of higher incidence of cGVHD in the recipients of peripheral blood stem cell transplantation compared with recipients of marrow transplantation. 29 Furthermore, extensive cGVHD is more common in the recipients of peripheral blood stem cell transplant. 30, 31 Cellular composition of the peripheral stem cell graft, which contained high numbers of Th2 lymphocytes 32 and/or CD14 þ cells 33 might have contributed to the relatively low incidence of acute GVHD but increased the risk of extensive cGVHD.
The pathophysiology of cGVHD is poorly understood. Autoantibody formation as detected in patients with cGVHD has also been noted in experimental models of cGVHD. [34] [35] [36] [37] However, renal involvement, an important and common feature in murine models, has been seldom reported in humans. Most patients with cGVHD, as in the murine models, have evidence of B-cell dysregulation with a high prevalence of autoantibodies to several cell surface and intracellular antigens, 35, 37 as well as antibodies directed against minor histocompatibility antigens. 38 The role of these antibodies in the pathogenesis of the disease is unknown. B-cell alloreactivity to minor histocompatibility antigens is believed to play a role in the pathogenesis of cGVHD in humans. [39] [40] [41] Response of two patients to B-cell depletion with anti-CD20 antibody provided clinical evidence supporting the pathogenic role of B-cell involvement in the renal pathology and other manifestation of cGVHD. 39, 42 Storb and co-workers demonstrated that allogeneic donor cells can seed the aortic graft endothelium in canine models suggesting an intriguing possibility is the seeding of host renal vasculature with donor-derived cells that set of an autoimmune response in the donor T-cell associated with donor B-cell dysregulation against donorderived antigens. 27 GVHD is fundamentally mediated by the allo-reactive donor T-cells responding to host minor histocompatibility antigens (miHA). Despite the evidence of B-cell dysregulation after HCT, whether this is a directly related to the induction/perpetuation of GVHD or is a consequence of altered CD4 þ T-cell help secondary to their allo-reactivity remains unknown. Recently Romagnani et al. demonstrated donor T-cell infiltration of renal tissue (identified by Y chromosome specific markers with immuno-histochemistry, laser micro-dissection and PCR analyses) in a patient that presented with NS after a HLA-matched male to female MRD HCT. 28 Yet another study demonstrated a contemporaneous increase in the expression of TNF-a and IFN-g in the donor T cells and the occurrence of NS following the withdrawal of immunosuppression after allogeneic HCT. 43 Together, these studies suggest a key role for T-cells in the occurrence of this syndrome after HCT. However, in light of no reported evidence of NS after liver or cardiac allo-grafting in the absence of concomitant HCV viremia, whether T-cell allo-reactivity alone is sufficient to induce NS remains speculative. Therefore, the exact pathophysiology of NS associated with GVHD post-HCT remains is as yet unknown and it is likely to due to a consequence of the combination of complex interactions between allo-reactive T-cells, the nature of miHA mismatches, the cytokine milieu, the preparative regimen, B-cell dysregulation and perhaps even the underlying disease.
NS is generally known run a variable course with a third of patients responding spontaneously. Furthermore, given the difficulties associated with a uniform diagnosis of the severity and the complicated clinical course of cGVHD, NS may be under-diagnosed after allogeneic HCT. An appropriate degree of clinical suspicion, accompanied by renal biopsy, is needed to reliably diagnose this manifestation of cGVHD. Larger studies with prospective screening are required to clearly determine the true incidence of this entity after allogeneic HCT and its association with GVHD.
